Author

M.A. de Korte

Observed names: M A de Korte, M Korte, M. A. De Korte, M. Alexander de Korte, Miguel Korte

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), University Medical Center Groningen, University of Groningen, Erasmus MC Cancer Institute

OpenAlex ID: A5111978656

Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

2006 · Patrick J. Perik, Marjolijn N. Lub-De Hooge, et al. · Journal of Clinical Oncology · 313

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity

2007 · M.A. de Korte, E.G.E. de Vries, et al. · European Journal of Cancer · 161

Molecular imaging: what can be used today

2005 · P. L. Jager, M A de Korte, et al. · Cancer Imaging · 47

Minimum requirements for the introduction of immuno-oncology medicines in low-and lower middle-income countries

2023 · Tosin Adeyemo, Tim Wilsdon, et al. · International Journal of Healthcare Management · 2

Ex vivo functional assay for predicting radiation treatment response in squamous cell carcinoma of the head and neck

2021 · M.E. Capala, G.M. Verduijn, et al. · Oral Oncology · 1

VEGF Immuno-PET with (89)Zr-ranibizumab during sunitinib treatment

2010 · Marjolijn N. Lub–de Hooge, WB Nagengast, et al. · European Journal of Nuclear Medicine and Molecular Imaging

Myocardial HER2 expression with 111In-DTPA-trastuzmab scan in patients shortly after anthracycline treatment

2006 · P. J. Perik, M. N. Lub-De Hooge, et al. · Journal of Clinical Oncology

[Complicated course of rheumatoid arthritis with pulmonary involvement, myocardial fibrosis and sleep apnea syndrome].

1997 · M Korte · PubMed

Works count: 8

Citation count: 524

H-index: 3

I10-index: 3